You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 24, 2024

CLINICAL TRIALS PROFILE FOR INTERFERON ALFA-2B


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for interferon alfa-2b

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000401 ↗ Oral Collagen for Rheumatoid Arthritis Completed National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Phase 2 1999-07-01 Rheumatoid arthritis (RA) is an autoimmune disease characterized by swelling and inflammation of the joints. In RA, the immune system attacks a person's own cells inside joints, eventually leading to joint damage and disability. This study will determine if oral bovine type II collagen (bovine CII) will lead to decreased joint inflammation in RA patients.
NCT00000401 ↗ Oral Collagen for Rheumatoid Arthritis Completed University of Tennessee Phase 2 1999-07-01 Rheumatoid arthritis (RA) is an autoimmune disease characterized by swelling and inflammation of the joints. In RA, the immune system attacks a person's own cells inside joints, eventually leading to joint damage and disability. This study will determine if oral bovine type II collagen (bovine CII) will lead to decreased joint inflammation in RA patients.
NCT00000647 ↗ An Open Trial Combining Zidovudine, Interferon-alfa, and Recombinant CD4-IgG With Transplantation of Syngeneic Bone Marrow and Peripheral Blood Lymphocytes From Healthy gp160-Immunized Donors in the Treatment of Patients With HIV Infection Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 To restore immunologic function and virus-free state in HIV-infected patients. Based on previous studies showing temporary improvement in immune function in HIV-infected patients using peripheral lymphocyte transfers and bone marrow transplantation, and based on studies documenting the antiretroviral effects of zidovudine (AZT) and interferon-alfa (IFN-A) as well as the preliminary test tube and patient studies suggesting anti-HIV effects of recombinant CD4-IgG, we propose to treat HIV-infected patients using combination antiretroviral therapy with transplantation of bone marrow and peripheral lymphocytes from previously immunized donors in an attempt to restore immunologic function and a virus-free state.
NCT00000687 ↗ Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 1969-12-31 To determine the safety and effectiveness of combining zidovudine (AZT) and interferon alfa-2a (IFN-A2a) in a treatment for Kaposi's sarcoma (KS) in patients who have AIDS. It is hoped with the present study to define the rate at which the treatment affects the tumors and also to assess any toxic effects of the combination treatment over a period of time. In a recent study, the combination of IFN-A2a and AZT in the treatment of patients with AIDS-associated KS was evaluated and safe doses of both AZT and IFN-A2a were determined. In addition, it appeared that there was a substantial reduction in KS lesions with this therapy. Potential benefits of this combined therapy include resolution of KS lesions, prolonged survival, a decrease in the frequency and severity of opportunistic infections, improvement in CD4 cells, and a decrease in serum p24 antigens.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for interferon alfa-2b

Condition Name

Condition Name for interferon alfa-2b
Intervention Trials
Hepatitis C 224
Hepatitis C, Chronic 140
Chronic Hepatitis C 124
Multiple Sclerosis 81
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for interferon alfa-2b
Intervention Trials
Hepatitis 685
Hepatitis C 608
Hepatitis A 591
Hepatitis, Chronic 371
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for interferon alfa-2b

Trials by Country

Trials by Country for interferon alfa-2b
Location Trials
Canada 422
Korea, Republic of 90
Taiwan 88
Netherlands 85
Puerto Rico 82
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for interferon alfa-2b
Location Trials
Texas 274
California 266
New York 253
Maryland 217
Florida 195
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for interferon alfa-2b

Clinical Trial Phase

Clinical Trial Phase for interferon alfa-2b
Clinical Trial Phase Trials
Phase 4 278
Phase 3 392
Phase 2/Phase 3 62
[disabled in preview] 650
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for interferon alfa-2b
Clinical Trial Phase Trials
Completed 1119
Unknown status 202
Terminated 188
[disabled in preview] 156
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for interferon alfa-2b

Sponsor Name

Sponsor Name for interferon alfa-2b
Sponsor Trials
National Cancer Institute (NCI) 153
Hoffmann-La Roche 99
Merck Sharp & Dohme Corp. 87
[disabled in preview] 84
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for interferon alfa-2b
Sponsor Trials
Other 1849
Industry 1063
NIH 314
[disabled in preview] 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.